PHARMACY

Pfizer completes Hospira acquisition

BY David Salazar

NEW YORK — Pfizer this week announced that it had completed its acquisition of injectable and infusion drug maker Hospira. Pfizer said that the transaction has strengthened the company’s branded and generics portfolio, particularly when it comes to biosimilars, the market for which is expected to hit $20 billion in 2020, and the first of which was launched in the U.S. on Thursday.

“Together, we are … a leading global biosimilars company with a robust pipeline, best-in-class development capabilities and extensive real-world commercialization experience,” John Young, group president global established pharmaceutical business, said. “By increasing the number and availability of high-quality generic injectable drugs and biosimilars that we offer our customers, we are strengthening our commitment to improving the health and quality of life of patients around the world with high quality medicines across key therapeutic areas.”

The company expects the transaction to boost earnings per share by about $0.10 to $0.12 per share in the year after closing, and will adjust its 2015 guidance to incorporate Hospira in the coming weeks.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lupin launches Cymbalta generic

BY Alex Tomas

BALTIMORE — Lupin Pharmaceuticals on Thursday announced the launch of its duloxetine delayed-release, a generic version of Cymbalta. The drug is available in 20-, 30-, 40- and 60-mg. The company said that its 40-mg strength is among the first generic duloxetine in that strength.

Duloxetine is meant to treat patients with major depressive disorder, generalized anxiety disorder, chronic musculoskeletal pain and diabetic peripheral neuropathic pain. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Good Neighbor Pharmacy tops J.D Power customer satisfaction study

BY DSN STAFF

VALLEY FORGE, Pa. — J.D. Power’s annual U.S. Pharmacy Study has ranked AmerisourceBergen’s Good Neighbor Pharmacy network the highest in customer satisfaction among chain drug stores. This is the third year in a row that the independent pharmacy network has topped J.D. Power’s study. J.D. Power also gave Good Neighbor Pharmacy the highest of its Power Circle ratings, which are based on feedback from product and service owners.

Good Neighbor Pharmacy received a Customer Satisfaction Index score of 876 out of 1,000 — higher than the average chain drug store score of 842. The study ranks customer satisfaction based on customer feedback for a company’s competitiveness, cost, pharmacist and non-pharmacist staff, and this year’s study looked to 15,000 customers.  

“As some of the most accessible healthcare providers, pharmacists have grown, and should continue to grow, their role in driving positive health behaviors and outcomes in their communities,” Good Neighbor Pharmacy President Dave Neu said. “The recognition by J.D. Power is a tremendous honor and indicative of the efforts and achievements of the thousands of independent pharmacists who make up Good Neighbor Pharmacy.”

Some general insights that the study revealed include the fact that a pharmacist’s individual attention can have an impact on loyalty, as 44% of customers who talk to their pharmacists strongly agree that they feel loyal to a pharmacy, compared with 35% of people who don’t talk to a pharmacist. Additionally, front-end sales can be aided by offering health services, as 60% of customers who take advantage of the services buy other merchandise from the pharmacy.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?